Differentiating FcRn-Targeted Therapies in MG Clinical Practice

This episode, titled ‘Differentiating FcRn-Targeted Therapies in MG Clinical Practice,’ features panelists examining clinically relevant differences among available FcRn-targeted therapies. The experts compare efgartigimod, rozanolixizumab, and nipocalimab, emphasizing that although each therapy reduces circulating IgG through FcRn, they are distinct molecules with differences in structure, binding characteristics, administration, and dosing strategy.

The discussion highlights practical differences between cyclic and continuous treatment approaches. Efgartigimod and rozanolixizumab were initially developed with cyclic or need-based treatment strategies, whereas nipocalimab is administered intravenously on a fixed every-other-week schedule. Faculty also discuss differences in the degree of IgG reduction observed with the individual agents while cautioning that available evidence does not establish that greater IgG reduction necessarily translates into superior clinical efficacy.

The panel stresses the importance of individualized treatment selection. Route of administration, preference for intravenous or subcutaneous treatment, cyclic versus continuous dosing, lifestyle considerations, and the possibility of symptom recurrence between cycles may all affect the suitability of a particular FcRn therapy. Importantly, the experts note that a patient's response to one FcRn-targeted agent may not necessarily predict response to another. This creates a rationale for reassessing the specific molecule or dosing approach when treatment response is incomplete rather than automatically assuming failure of the entire therapeutic class.

In the next episode, ‘Evaluating Clinical Evidence for FcRn-Targeted Therapies in MG,’ panelists will review clinical findings with nipocalimab, efgartigimod, and rozanolixizumab and consider how depth, durability, and speed of response may translate into practice.